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Abstract
In this position paper, the European Society for Clinical Microbiology and Infectious Diseases, Study Group on
Clinical Parasitology, summarizes main issues regarding the management of imported malaria cases. Malaria is a
rare diagnosis in Europe, but it is a medical emergency. A travel history is the key to suspecting malaria and is
mandatory in patients with fever. There are no specific clinical signs or symptoms of malaria although fever is
seen in almost all non-immune patients. Migrants from malaria endemic areas may have few symptoms.
Malaria diagnostics should be performed immediately on suspicion of malaria and the gold- standard is microscopy
of Giemsa-stained thick and thin blood films. A Rapid Diagnostic Test (RDT) may be used as an initial screening
tool, but does not replace urgent microscopy which should be done in parallel. Delays in microscopy, however,
should not lead to delayed initiation of appropriate treatment. Patients diagnosed with malaria should usually be
hospitalized. If outpatient management is preferred, as is the practice in some European centres, patients must
usually be followed closely (at least daily) until clinical and parasitological cure. Treatment of uncomplicated
Plasmodium falciparum malaria is either with oral artemisinin combination therapy (ACT) or with the combination
atovaquone/proguanil. Two forms of ACT are available in Europe: artemether/lumefantrine and dihydroartemisinin/
piperaquine. ACT is also effective against Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and
Plasmodium knowlesi, but these species can be treated with chloroquine. Treatment of persistent liver forms in
P. vivax and P. ovale with primaquine is indicated after excluding glucose 6 phosphate dehydrogenase deficiency.
There are modified schedules and drug options for the treatment of malaria in special patient groups, such as
children and pregnant women. The potential for drug interactions and the role of food in the absorption of
anti-malarials are important considerations in the choice of treatment.
Complicated malaria is treated with intravenous artesunate resulting in a much more rapid decrease in parasite
density compared to quinine. Patients treated with intravenous artesunate should be closely monitored for
haemolysis for four weeks after treatment. There is a concern in some countries about the lack of artesunate
produced according to Good Manufacturing Practice (GMP).
Background
Malaria continues to pose challenges in diagnosis and
management and remains an infrequently encountered
infection for many physicians in non-endemic areas.
Malaria symptoms are non-specific and cannot easily be
distinguished from a wide range of other febrile condi-
tions on clinical grounds alone [1]. Thus, a high degree
of suspicion is needed and a travel history is essential in
any febrile patient presenting with non-specific, often
flu-like symptoms and signs.
Malaria cannot be confirmed clinically. The gold
standard for malaria diagnosis is light microscopy of
Giemsa-stained thin and thick blood films, which
requires a high level of expertise. This is not always
available around the clock outside specialized centres
and rapid diagnostic tests (RDTs) are, therefore, increas-
ingly used. However, RDTs have limitations and once a
malaria diagnosis has been made, the infecting species
present must be determined. Furthermore, in the case
of Plasmodium falciparum or Plasmodium knowlesi, the
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parasitaemia (expressed as number of parasites per
microlitre of blood or as a percentage of red cells
infected) is an essential parameter for determining
whether the patient has complicated malaria or not, and
to monitor treatment effect.
The management of malaria in non-endemic areas
may vary between centres. For example, in a retrospect-
ive analysis of over 500 patients from five European
countries treated between 2003 and 2009, 18 different
combination regimens were used [2]. To standardize
management based on current evidence, this paper
reviews malaria management for non-specialists and
advocates how it should be practised in Europe.
Short epidemiology of imported malaria
Malaria is one of the major global public health chal-
lenges with an estimated 225 million clinical cases
and more than 655.000 deaths in 2011, mainly in
children aged less than five years old from sub-Saharan
Africa. However, recent studies have found that the mor-
tality may be grossly underestimated [3,4,5]. In Europe,
malaria has been eradicated except in Azerbaijan,
Georgia, Kyrgyzstan, Tajikistan and Turkey [6]. It is esti-
mated that 25–30 million individuals travel annually
from Europe to areas with malaria transmission.
Malaria imported to Europe is seen in travellers
returning from or migrants coming from endemic areas
and migrants living in Europe returning from visiting
friends and relatives (VFR). VFR children are particularly
at risk. In 2010, WHO reports that 6,244 cases of
malaria were imported in Europe down from 14,703
cases in 2000 [6], however, this is considered to be
an underestimation and the numbers may be six-fold
greater [3] and this decrease in numbers contradicts
national studies, which all indicate an increasing number
of imported cases. Latest data from the UK [7] and
Europe [8] show increasing trends in imported malaria
and the latest US statistics show an increase of 14% in
imported malaria for 2010 [9]. The majority of imported
cases remains uncomplicated [1], and the mortality of
imported Plasmodium falciparum malaria cases varies
from 0.4% in a large cohort from France up to 5% in
a recent cluster of cases imported from The Gambia
[10,11].
The malaria programme in the WHO European
Region, reported an eight-fold increase in the number of
imported malaria cases between 1972 and 1988 (from
1,500 to 12,000 cases), followed by a more gradual rise
in 2000 (15,500 cases) with France, the UK, Germany
and Italy accounting for more than 70% of all cases [12].
One study found that the crude risk for travellers varied
from 1 per 100,000 travellers to Central America and
the Caribbean to 357 per 100,000 in Central Africa [13].
More than five million African migrants may currently
be living in Europe, one third of them originating from
sub-Saharan Africa [14]. The proportion of imported
malaria cases due to migrants in Europe has increased
during recent years from 14% to 83% [15-18]. VFRs trav-
elling to sub-Saharan Africa have more than eight times
the risk of being diagnosed with malaria compared to
tourists, and more than twice the odds of being diag-
nosed of malaria after travel to Asia [19]. VFR children
are particularly at risk [20].
Malaria infection among migrants, for example,
asymptomatic individuals with sub-microscopic parasit-
aemia, could increase the risk of transmission leading to
re-introduction of malaria in certain areas that have
competent vectors and climatic conditions as seen in
Greece in 2011 [21]. Moreover, imported malaria infec-
tions in migrants can also play a role in non-vectorial
transmission, through blood transfusion, organ trans-
plantation or occupational exposure.
Migrants commonly believe they are immune to mal-
aria [22], but their immunity wanes after arriving in
Europe. The low risk perception means that this group
rarely seeks pre-travel advice [7,23-25]. The incidence of
P. ovale infections and mixed infections is very similar
to the incidence found in West Africans [26-29].
Rare modes of transmission mean that patients with
fever and without a travel history to endemic areas
might need to be tested for malaria. These include so
called “airport malaria” where Anopheles mosquitoes
carrying malaria parasites are transported by aeroplane
to a non-endemic area and take a blood meal from
someone living close to the destination airport [30,31],
and “baggage malaria” [32]. Malaria parasites can also be
transmitted in blood as a consequence of intravenous
drug use [33]. Transmission of malaria by blood transfu-
sion from asymptomatic carriers is a major problem in
tropical Africa [34] and febrile patients with a history of
blood transfusion from a donor in or from a malaria-
endemic area should be suspected to have malaria until
proven otherwise. Congenital transmission or transmis-
sion by organ transplantation may also occur [35].
Pathophysiology
The pathophysiology of malaria involves the cytoad-
herence of infected erythrocytes (discussed below) and
consequent microvascular obstruction, as well as destruc-
tion of infected erythrocytes and the host’s response
to the released substances. Chills and fever are asso-
ciated with high levels of tumour necrosis factor released
from monocytes stimulated by antigens released by
bursting schizonts. Thrombocytopenia may be immune-
mediated or due to activation of the coagulation cascade
[36]. Anaemia is a consequence of intravascular lysis of
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infected erythrocytes, impaired bone marrow responses
and increased clearance of uninfected red cells.
P. falciparum-infected erythrocytes adhere to micro-
vascular endothelium in a process known as sequestra-
tion, which allows them to avoid being removed in the
spleen. This is favoured by other processes, such as a
reduction of red cell deformability, rosetting of non-
infected erythrocytes around the infected erythrocytes,
platelet-mediated aggregation of infected erythrocytes
[37-41]. Sequestration is seen especially in the small
venules of vital organs (brain - predominantly in white
matter, heart, lung, liver, kidneys, eyes) [42,43]. Seques-
tering of the erythrocytes in areas with low oxygen
tension may favour survival of the parasites. It has been
proposed that cerebral malaria is part of a heterogeneous
clinical presentation involving multi-system dysfunction
and acidosis [44]. A study of volume depletion in chil-
dren with malaria demonstrated that lactate (arterial)
was increased at admission [45], that volume depletion
was not severe and that lactate is the best indicator for
tissue perfusion and acidosis.
Clinical symptoms
Clinical symptoms in non-immunes (persons not born
and raised in endemic areas)
Most infections due to P. falciparum become symptom-
atic within 30 days after return from the malaria
endemic area, but longer incubation periods are seen
with the other species and are prolonged by incomplete
malaria chemoprophylaxis which may suppress parasit-
aemia without achieving full protection. A recent study
from Portugal including 284 patients (46% non-
immunes and 54% semi-immunes) found that the diag-
nosis was made between the day of return from the
malarious area and up to 47 days later; a single non-
immune patient was first diagnosed on the 120th day
after leaving Angola [46].
Prodromal symptoms, which may precede the fever
for up to two days are fatigue, loss of appetite, headache
and body pains. In non-immune patients, malaria usually
starts suddenly with a severe feeling of sickness and
fever - often reaching 39°C and higher [1]. Not all
patients show typical fever paroxysms and absence of
fever does not remove the suspicion of malaria in an ill
patient. A regular fever pattern is not always present.
If present, the frequency of the febrile episodes depends
on the parasite species, occurring every 48 hours
(tertian) for P. vivax and P. ovale, every 72 hours
(quartan) for P. malariae and 24 hours (quotidian) for
P. knowlesi. In P. falciparum malaria the fever usually
lacks a regular pattern.
Common symptoms are headache and myalgia. Other
symptoms may include nausea, vomiting, dry cough,
icterus, confusion and respiratory distress. Compromised
circulation leads to renal failure and impaired tissue per-
fusion resulting in acidosis. Gastrointestinal complaints
unrelated to treatment, including vomiting and diarrhoea
are less frequent. Patients with significant fever parox-
ysms may initially have a normal temperature between
the fevers and feel relatively well.
Clinical examination is non-specific or even completely
unremarkable. It often takes some days before anaemia
or hepatosplenomegaly develop. Coryza, swelling of
lymph nodes and eosinophilia are not seen in malaria.
Clinical symptoms in persons migrating from malaria
endemic areas
Malaria in adult migrants is characterized by a milder
clinical presentation, lower levels of parasitaemia, shorter
parasite clearance time after treatment and shorter fever
duration compared to malaria in travellers due to previ-
ously acquired semi-immunity [29,47-49]. Children born
in Europe to migrant parents are not immune.
A high proportion of migrants have few symptoms
and present long after arrival in the host country [50],
with periods of months up to more than 14 years
recorded [50-54]. If semi-immunity is lost, migrants
who travel to their country of origin would have a risk
of clinical malaria approaching that of travellers born in
non-endemic countries, however a degree of clinical
immunity against severe malaria is often retained. A
high prevalence (from 7.1% to 31.8%) of P. falciparum
infection (detected by PCR) has been found among
asymptomatic sub-Saharan African migrants after their
migration to Europe [48,55,56].
Indications for malaria diagnosis
Diagnostic tests for malaria should be performed in any
ill patient who has a history of exposure, i.e. patients
with a history of travel to malaria-endemic areas,
whether or not they are febrile at presentation [57].
Pregnant women visiting endemic areas or arriving
from areas of malaria transmission are at greater risk of
clinical malaria during pregnancy [50] than non-pregnant
women. Malaria parasites cross the placenta and conse-
quently the disease can occur in newborns from asymp-
tomatic mothers [58,59]. Splenectomized patients may
have more severe symptoms [60].
Laboratory results (other than tests for malaria parasites)
Most parameters are non-specific. Normochromic nor-
mocytic anaemia is observed in the majority of infected
patients, but is rare in the first few days of illness. The
most consistent finding is thrombocytopaenia and a
study from the UK found that children with malaria and
a platelet count of < 50,000 per ml had an odds ratio of
8.3 for admission to intensive care units [61]. As the
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infection progresses, haemolysis is indicated by elevated
LDH, free haemoglobin and low haptoglobin.
Although commonly unaffected except in case of a
secondary infection (often with non-typhoidal salmo-
nellae), the leucocyte count may be raised or greatly
diminished in very severe malaria cases and there may
be slight monocytosis and lymphocytopenia. The C-reactive
protein, procalcitonin, fibrinogen, orosomucoid and
cytokine levels are raised in acute malaria. Thrombo-
cytopaenia with a lower concentration of fibrinogen
and elevated fibrin degradation products strongly sug-
gest disseminated intravascular coagulation (DIC).
Moderate hyponatraemia can be seen, but plasma po-
tassium level is normal [62]. Bicarbonate concentra-
tion is reduced and lactate may be elevated in
metabolic acidosis, and arterial lactate is a better mar-
ker for acidosis than venous standard bicarbonate.
Serum creatinine and urea, total and conjugated bili-
rubin and liver transaminases may be raised, and a
slight elevation of hepatic alkaline phosphatase may
be seen. Hypoglycaemia may occur and, in the ab-
sence of quinine treatment is accompanied by other
signs related to high parasitaemia and severe acidosis
[63]. Laboratory indicators of a poor clinical prog-
nosis in severe malaria cases are shown in Table 1.
Blood cultures should be obtained on admission as mal-
aria infection can be complicated by septicaemia [64,65].
All patients with malaria should have the following
obtained at the time of diagnosis: haemoglobin, MCV,
MCHC, differential leucocyte count, platelets, blood urea
nitrogen or creatinine, alanine transferase, basic phos-
phatase and LDH. In complicated malaria this should be
supplemented with tests for DIC and arterial blood
for pH, lactate (arterial), blood gases and blood cul-
tures. Additional potentially useful parameters include
chest x-ray, urine culture and urine leukocytes, ECG,
potassium, urea, ALT, LDH, haptoglobin, fibrinogen.
Diagnostic procedures for malaria parasites including
parasitaemia
Microscopic examination of Giemsa-stained thin and
thick blood films remains the gold standard because it is
rapid, easy to perform and sensitive [66] with a sensitiv-
ity down to five parasites per microlitre in expert hands
[67]. Thick blood films are combined with thin blood
films as identification of the infecting species is much
more easily accomplished using a well-stained thin film.
However, the volume of blood examined in 100 high
power fields on a thick blood film is approximately
50 times more than in 100 high power fields of a thin
blood film, so malaria cannot be excluded based on
negative examination of only a thin blood film.
Early diagnosis is important to prevent uncomplicated
malaria progressing to complicated disease. Patients with
malaria should be managed in centres with the ability to
quantify the parasitaemia (usually expressed as the num-
ber of parasites per microlitre of blood or as the per-
centage of red cells containing malaria parasites). After
the start of treatment, there is a lag-phase before
the parasite density begins to decline [68] and there
may even be an increase in the first 24 hours after start-
ing treatment.
For falciparum malaria, many RDTs show 100% para-
site detection score down to a parasite density level of
200 parasites per microlitre, equivalent to a parasitaemia
of approximately 0.004% [69]. Polymerase chain reaction
(PCR) can detect parasites down to a density of 0.01
parasites per microlitre after a lysis procedure and
1 parasite per microlitre without lysis [70]. However,
PCR analysis is not instantly available around the clock
so in practice, diagnosis relies on RDTs and light micros-
copy of Giemsa-stained thin and thick blood films. PCR
is, however, very useful in partially treated cases, in sub-
microscopic malaria in immigrants and in detection of
mixed parasitaemia.
RDTs are increasingly used in medical centres with
limited access to experienced microscopists, however,
Table 1 Laboratory indicators of a poor clinical prognosis
in severe malaria
Hyperparasitaemia: > 250.000/ul or > 2% of infected
erythrocytes in non-immunes and
> 5% in semi-immune individuals
Schizonts of P. falciparum in
peripheral blood
Mature pigmented parasites (> 20%
of parasites)
Peripheral blood leukocytes with ingested hemozoin (>5%)
Haemoglobin < 5 g/dl or packed cell volume< 0.15
Polymorphonuclear leukocytes > 12.000/ul
Coagulation disturbancies Platelets < 50.000/ul
Prothrombin time prolonged> 3 sec
Prolonged partial thromboplastin time
Fibrinogen < 200 mg/dl
Low antithrombin III levels
Hypoglycaemia < 2.2 mmol/l (< 40 mg/dl)
Acid-base disturbancies Venous HCO3< 15 mmol/l and/or
arterial pH< 7.3
Lactate > 5 mmol/l
Kidney function Serum creatinine > 3.0 mg/dl
(> 265 mmol/l)
Blood urea nitrogen> 60 mg/dl
Liver function More than 3-fold elevation of
aminotransferases (AST, ALT)
Cerebrospinal fluid High CSF lactic acid (> 6 mmol/l)
and low CSF glucose concentration
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a rapid test cannot determine the parasite density.
False negative RDTs in patients with very high parasite
densities have been described, probably due to the so-
called “pro-zone” phenomenon [71,72]. This problem
seems to be limited to tests based on detection of Histi-
dine Rich Protein 2, HRP2 [71]. Mutations in the HRP2
gene may also result in false negative tests [73,74] and
rheumatoid factor may lead to false positives [75].
Assays are available that detect all species i.e. P. falcip-
arum, P. vivax, P. ovale, P. malariae, and P. knowlesi
based on the detection of pan-malarial antigens aldolase
and LDH antigen [76]. Plasmodium knowlesi infections
will be detected by rapid tests which include the pan
plasmodial aldolase or LDH antigens [69,77]. The latest
results of the WHO multi-centre evaluation of different
rapid diagnostic tests show that the best performance
was found with tests based on a combination of the
HRP2 and pan plasmodial proteins [69]. Clinicians using
rapid tests should be instructed that no RDT test so far
is 100% reliable and that they should be used in parallel
to and not instead of blood film examination. In order
to reduce the risk of missing malaria, testing with blood
films and RDTs should be performed on three blood
samples taken at daily intervals for patients with high
suspicion for malaria. If the suspicion of malaria remains
after three negative samples, expert advice should be
obtained from a tropical or infectious diseases specialist.
Once the diagnosis has been made, the patient should
have daily blood films until they are negative for asexual
parasites (ie. rings, trophozoites, schizonts). Gametocytes
do not multiply or cause clinical illness and may remain
after clearance of the asexual parasitaemia.
Treatment of uncomplicated P. falciparum malaria
Treatment should provide rapid clinical and parasito-
logical cure within three days. Oral ACT is the standard
treatment of uncomplicated malaria as recommended by
WHO [78,79] (Table 2). Currently, artemether/lumefan-
trine, and dihydroartemisinin/piperaquine, a ACT formu-
lation registered by the European Medicines Agency,
EMA, are licensed for use in Europe. Artemether/lume-
fantrine is the most widely-used ACT globally, is well tol-
erated and highly efficacious in all endemic regions except
for P. falciparum infections acquired in Cambodia and the
border regions of Thailand with Myanmar, where multi-
drug resistant P. falciparum strains are highly prevalent.
Artemether/lumefantrine has to be administered with
fatty food to obtain optimal plasma drug concentrations
[80]. Dihydroartemisinin/piperaquine is a newly regis-
tered ACT with proven high efficacy and a favourable
tolerability profile. It has been extensively used in
malaria-endemic regions and marketing in European
countries has started. Dihydroartemisinin/piperaquine
should be taken fasting (Table 3).
Atovaquone-proguanil can be used as first-line treat-
ment for uncomplicated malaria and needs to be adminis-
tered with fatty food to increase bioavailability (Table 3).
Atovaquone/proguanil is relatively slow acting with con-
siderably longer parasite clearance times compared to
ACT (Table 4). Atovaquone/proguanil is the preferred
treatment option for uncomplicated falciparum malaria
from regions with artemisinin resistance (Cambodia,
Thailand border regions).
Second-line anti-malarial treatments used when first-
line anti-malarials are not available or excluded due to
other reasons such as intolerance include mefloquine
monotherapy for infections originating from regions
without established mefloquine resistance (high preva-
lence of mefloquine resistance is common in Thailand,
Myanmar and Cambodia). The use of mefloquine at
treatment doses has been associated with a significantly
higher incidence of serious neuropsychiatric adverse
events [81]. Combinations of quinine with either doxy-
cycline or clindamycin are also considered second line
treatment options.
Quinine drug combinations have excellent efficacy, but
tolerability is generally poor due to prolonged treatment
courses and the occurrence of characteristic adverse
effects (cinchonism) [82]. The WHO guidelines consider
quinine plus tetracycline or clindamycine as alternative
first-line treatments, but the study group is of the
opinion that ACT should be the first line choice in
Europe [79].
The use of chloroquine is not recommended for the
treatment of P. falciparum malaria because of wide-
spread resistance. However, chloroquine remains effect-
ive in Haiti, Dominican Republic, Middle East and
Central America north of the Panama Canal, and may
be considered as an alternative treatment if ACT cannot
be used.
In the case of failed anti-malarial chemoprophylaxis,
an anti-malarial drug different from the chemoprophy-
lactic drug taken should be used for treatment. Finally,
it is important to note that despite the fact that oral
anti-malarials are recommended for the treatment of
uncomplicated malaria, it is sometimes necessary for the
responsible physician to use intravenous treatment with
artesunate or quinine as recommended for the treatment
of severe malaria. This decision may be taken based
on evidence of important co-morbidities, intractable
vomiting, or on clinical concern of the physician. The
clinical criteria for severe malaria are shown in Table 4.
Recently, the WHO defined a parasitaemia of 2% or
more as severe malaria in non-immunes and 5% or
more in patients from endemic areas [79].
Patients suffering from P. falciparum malaria should,
in general, be admitted to hospital, since monitoring of
prognostic parameters including parasitaemia, treatment
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adherence and if needed, transfer to intensive care units,
would normally be instantly available. Repeated monitoring
of blood pressure, urinary output and oxygen saturation
may be indicated. However, management as outpatients
may be considered in uncomplicated cases in some health-
care systems where daily follow up until clearance of para-
sitaemia and fever and monitoring of treatment adherence
can be undertaken. Persons migrating from malaria ende-
mic regions may fall into this category.
Treatment of complicated falciparum malaria
The clinical criteria for severe malaria are shown in
Table 4. Severe malaria may also be caused by species
other than P. falciparum, especially P. knowlesi. Plasmo-
dium vivax can be severe in non-immunes [83]. The
criteria for the definition of severe malaria were deter-
mined by studies carried out in endemic areas and their
relevance to imported malaria in Europe remains con-
troversial. However, these criteria may be adapted to the
European context [84].
Choice of drugs
Severe imported P. falciparum malaria is an emergency
which may become rapidly fatal [85]. Intravenous artesu-
nate is the drug of choice [79] and a recent Cochrane
review concluded that treatment with artesunate signifi-
cantly reduced the risk of death both in adults (RR 0.61,
95% Confidence Interval (CI) 0.50 to 0.75; 1664 partici-
pants, five trials) and children (RR 0.76, 95% CI 0.65 to
0.90; 5765 participants, four trials) [86]. Intravenous
artesunate must be started immediately after the con-
firmation of the diagnosis and the patients transferred to
the ICU for management.
Intravenous artesunate (IVA)
IVA is superior to intravenous quinine (IVQ) in overall
survival and safer and simpler to administer [86-89].
IVA contains artemisinin hemisuccinate 60 mg/ml and is
reconstituted with 3 to 5 ml dextrose 5% and immedi-
ately administered in a bolus. IVA is administered as
2.4 mg per kilogram of body weight every 12 hours on
Table 3 Important food – anti-malarial drug interactions
Drug Dietary recommendations Mechanism of interaction Practical consequence
Atovaquone Take with fatty meal Increased solubility and absorbtion Increased drug levels
Artemether/lumefantrine Take with food Lumefantrine is lipophilic (fat soluble) Up to 16-fold increased drug levels
Dihydroartemisinin/piperaquine Take on an empty stomach
(fasting)
Food increases absorption of piperaquine Reduces risk of QTc prolongation
Doxycycline Without milk Milk chelates tetracyclines and reduces
absorption
Low drug concentrations and
treatment failure
Mefloquine With food Increased solubility and absorbtion Increased drug levels
Primaquine With food Increased solubility and absorbtion Increased drug levels
Table 2 Treatment of uncomplicated falciparum malaria in adults [79]
Adult Patients
Drug Dosage Comment
First line Artemether/Lumefantrine (Riamet™) Twice daily for three days >35 kg:
4 tablets each 20 mg/120 mg for
6 doses (0–8–24–36–48–60 hours)
Take with fatty food, reduced efficacy
in Cambodia and border regions
of Thailand
Dihydroartemisinin/Piperaquine
(Eurartesim™)°
Once daily for three days 36 <75 kg:
3 tablets each 320 mg/40 mg, 75-100 kg:
4 tablets each 320 mg/40 mg, daily for three days
Administration without food, at least
3 hours from any meal
Atovaquone/Proguanil (Malarone™) Once daily for 3 days >40 kg: 4 tablets
each 250/100 mg
Administration with fatty food
Second line Quinine*/Doxycycline Thrice daily 10 mg/kg quinine plus
daily 200 mg doxycycline for 7 days
Loose drug combination, off-label use
Quinine*/Clindamycin Thrice daily 10 mg/kg quinine plus twice
daily 10 mg/kg clindamycin for 7 days
Loose drug combination, off-label use
Mefloquine (Lariam™) Split total dose in 2–3 doses 6–8 hours
apart 45-60 kg: 5 tablets (3 + 2 tablets)
>60 kg: 6 tablets (3 + 2 + 1 tablets)
Administration after food intake
monotherapy, which is not suitable
for regions with multidrug resistant
falciparum malaria (SE-Asia)
*Quinine dose provided as quinine sulphate °Eurartesim tablet strengths are Dihydroartemisinin/piperaquine 20 mg/160 mg and Dihydroartemisinin/piperaquine
40 mg/320 mg.
Askling et al. Malaria Journal 2012, 11:328 Page 6 of 15
http://www.malariajournal.com/content/11/1/328
day 1 and then once daily up to the total dose of 12 mg
per kilogram administered in five doses over 3 days [80].
IVA should be the drug of choice for treatment of severe
imported malaria in Europe even though trials have only
been performed in endemic regions [89]. A recent study
reported haemolytic anaemia in six out of 25 patients
treated with IVA for severe imported malaria diagnosed
14–31 days after the first dose of IVA [90]. A larger
study including 55 patients with severe malaria reported
late onset haemolytic anaemia in six patients (9%) be-
tween 7 and 31 days after start of IVA [91] and three
more cases have just been reported [92]. Nevertheless, in
a large French study about 400 severe malaria patients
treated with IVQ in the ICU, 28.5% of them required
red blood cell transfusion for marked anaemia [84].
Until further data are available, patients should be moni-
tored for four weeks following IVA for haemolysis and
leukopaenia. IVA should be completed with a full course
of ACT, atovaquone/proguanil or mefloquine.
IVA produced under European Good Manufacturing
Practice (GMP) standards is not yet available. Neverthe-
less, in some European countries (particularly in France),
IVA manufactured in China (Guilin Pharmaceuticals)
has been approved by the National Drug Agency and is
now available with a specific temporary authorization of
use (see section: «unlicensed drugs » below).
Intravenous quinine (IVQ)
IVQ is the drug of choice if IVA is not immediately
available. An ECG should be obtained before starting
IVQ. Use of a loading dose is recommended to rapidly
obtain a therapeutic serum quinine level [84]. The load-
ing dose is 20 mg/kg quinine dihydrochloride in 10%
glucose or 0.9% sodium chloride infused over 4 hours.
Treatment is continued with 10 mg/kg quinine dihy-
drochloride by infusion over 4 h in 500 ml of 5% glu-
cose, every 8 h until parasitaemia is less than 1% and the
patient can take oral medication. Any previous treat-
ment with mefloquine or quinine and/or an increased
corrected QT interval >25%, are contra-indications for a
loading dose because of an increased risk of cardiotoxi-
city. Continuous monitoring of the cardiac rhythm is ne-
cessary. The only strict contra-indications to IVQ are a
documented previous history of blackwater fever [93],
hypersensitivity to quinine, and cardiac arrythmia. Black-
water fever may occur on quinine treatment [93].
A full seven day course of IVQ is rarely completed.
Quinine treatment can be changed either to an ACT or
to an oral quinine-antibiotic combination as soon as the
parasite density decreases and the patient tolerates oral
treatment. The same principles apply for intravenous
artesunate, where treatment is switched to oral ACT as
soon as the parasite density has fallen adequately. In
adults, doxycycline (or clindamycin during pregnancy)
should be used in association with quinine if the quinine
course cannot be followed by a course of ACT. Meflo-
quine should be avoided in patients with cerebral
malaria even in the recovery phase. IVQ should be com-
pleted with a full course of ACT, atovaquone/proguanil
or mefloquine.
Supportive care on ICU (Intensive Care Unit)
Amongst the various scoring systems for adult malaria
patients requiring ICU treatment outside endemic areas,
SAPS II and the WHO score appear to be most reliable
[46,84,94]. Fluid management is very important. Fluid
overload may cause pulmonary oedema [95]. The intra-
vascular volume should be high enough to ensure suffi-
cient systemic perfusion, but overhydration has to be
avoided, and adults with severe malaria are very vulner-
able to fluid overload [79]. Monitoring of plasma lactate
is mandatory. For children, the FEAST trial provided
high quality evidence that during paediatric malaria fluid
bolus significantly increases mortality [96]. The mainten-
ance of a particular central venous pressure in severe
malaria cannot be supported by available studies [97].
In adults with severe P. falciparum malaria there was no
Table 4 Severe manifestations of P. falciparum malaria in
adults (WHO 2000, adapted WHO 2011) [77,78]
Prognostic value Clinical manifestations and
laboratory findings
Frequency
(?) no data Prostration +++
+ Impaired consciousness
(score <11 on the Glasgow Coma Scale)
++
+++ Acute respiratory distress +
++ Multiple seizures +
+++ Circulatory collapse (systolic blood
pressure <80 mm Hg with features of
peripheral circulatory failure)
+
+++ Pulmonary oedema (radiological) +
++ Abnormal bleeding (clinically defined) +
+ Jaundice (clinically defined or serum
bilirubin >50 mol/L
+++
+ Macroscopic haemoglobinuria +
+ Severe anaemia (haemoglobin
<5 g/dL or haematocrit <15%)
+
+++ Hypoglycaemia (blood glucose
concentration <2.2 mmol/L)
++
+++ Acidosis (pH <7.35 or plasma
bicarbonate <15 mmol/L)
++
+++ High plasma lactate (>5 mmol/L) ++
++ High parasitemia (especially 2%
in non-immune patients and 5%
in semi-immune patients)
+
++ Acute renal failure
(serum creatinine > 265 μmol/L and
24-hour urine output <400 mL)
+++
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observed improvement in patient outcome or acid–base
status with fluid loading. Neither CVP (Central venous
Pressure) nor PAoP (Pulmonary Artery occlusion Pres-
sure) correlated with markers of end-organ perfusion or
respiratory status [98]. In the shocked and/or acidotic
patient with severe malaria, bacterial co-infection should
be sought by blood culture and antibiotic treatment
started urgently [94,99].
Acute renal impairment and failure is frequent and
indications for acute dialysis do not differ from acute
renal failure in other conditions. Hyponatraemia is often
seen in falciparum malaria, caused by reduced kidney
function and consecutive dilutional hyponatraemia or by
an Anti Diuretic Hormone Syndrome in the case of
euvolemia. In both cases, treatment is by fluid restric-
tion. Precise monitoring of the fluid balance is essential.
In the case of cerebral malaria the usual supportive
measures practiced in neurological intensive care medi-
cine are recommended. However, corticosteroids as well
as mannitol should not be given, as they lead to pro-
longation of coma time and worsen the prognosis [79].
Hypoglycaemia is often seen, especially with quinine
therapy and the blood sugar has to be monitored closely.
Mefloquine should be avoided in patients with cerebral
malaria even in the recovery phase because of the risk of
post-malaria neurological syndrome.
There is no consensus on the indications, benefits and
dangers involved in exchange blood transfusion, so it
should not be used [79]. Automated red blood cell ex-
change (i.e. erythrocytopheresis) is another potentially
useful adjunctive treatment option to rapidly reduce
high parasitaemia by removing infected erythrocytes. It
has the advantage of less interference with volume and
electrolyte status of the patient, but no randomized con-
trolled trial has been conducted so far [100,101] and its
role is unclear since the advent of ACT.
Unlicensed drugs
WHO guidelines recommend IVA in preference to quin-
ine for the treatment of severe malaria in adults [80]. At
present, no GMP (Good Manufacturing Practice) pro-
duced IVA is available in Europe. However, Guilin
Pharmaceutical Factory No. 2 (Shanghai, People’s Repub-
lic of China), the manufacturer of the artesunate used in
major trials in Southeast Asia and Africa [87,88], may
supply the drugs upon request. Artesunate manufactured
by Guilin has received pre-qualification from the WHO.
Since 2011, the French National Health Agency (AFS-
SAPS), now named (ANSM) has temporarily authorized
the import and use of IVA (MalacefW) via ACR-Pharma-
ceuticals, the Netherlands, granting it a temporary
authorization of use [102]. However, the use of non
GMP artesunate remains sensitive from a legal point of
view in many European countries, and some centres
have addressed this by using a combination of quinine
and artesunate, with satisfactory clinical outcomes and
no safety concerns in a limited series of patients [103].
Paediatric malaria
Paediatric dosages are provided in Table 5. For imported
cases, the risk of developing severe malaria is very high
in VFR children without acquired semi-immunity and
who are often more exposed to malaria [104]. Migrants’
children are less likely to complain of chills, arthralgia/
myalgia or headaches. The clinical approach to the treat-
ment of children is comparable to adult patients and re-
lies on the classification into uncomplicated and severe
falciparum malaria (Table 2). The clinical assessment of
young children may be more challenging in particular
when assessing potential alteration of mental status.
Prostration – the inability to walk, stand, sit, or feed – is
a useful clinical indicator for severe disease in endemic
regions, and it may be a particularly useful clinical indi-
cator for very young children.
In line with recommendations for adults, ACT and
atovaquone-proguanil are the recommended first-line
treatments for uncomplicated P. falciparum malaria in
paediatric patients in Europe (Table 5). Paediatric for-
mulations should be used if available [105].
Quinine-clindamycin or mefloquine mono-therapy
(except for regions with multi-drug resistant P. falcip-
arum strains such as the Thai-Myanmar-Cambodia re-
gion) are appropriate second line drugs. Tetracyclines
are contra-indicated in children below 8 years of age
(below 13 years in some countries).
The administration of drugs in general and the in-
tensely bitter taste of anti-malarials in particular (even
more so if adult tablets are crushed to improve the ease
of administration) is an important concern in young
children. The use of paediatric drug formulations has
been shown to improve the tolerability of antimalarials.
To date, artemether/lumefantrine and dihydroartemisinin/
piperaquine are useful first line paediatric anti-
malarials. Artmether/lumefantrine is available as a dis-
persible tablet formulation (registered in Switzerland
only). Atovaquone/proguanil is also available as paedi-
atric tablets. Anti-malarial treatment of severe malaria
in children follows similar algorithms as for adult
patients and is based on prompt administration of
intravenous artesunate (or quinine if artesunate is not
available). Children presenting with malaria are likely
to have high fever which increases the risk of vomit-
ing and seizures. Fever should be reduced by tepid
sponging and the use of an anti-pyretic such as para-
cetamol. which can be administered rectally, though
paracetamol prolongs parasite clearance times in
children.
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Bacterial infections including sepsis and meningitis are
more common in paediatric patients compared to adults
in malaria endemic regions, and blood culture should be
obtained on admission. Invasive non-typhoidal salmon-
ella infections are among the most common invasive
bacterial pathogens in some regions of Africa where
malaria is highly endemic [106].
Congenital transmission of malaria to the newborn
is a rare event and is estimated to occur in only 1%
of newborns delivered by mothers with malaria. Clin-
ical disease in the infant usually develops 2–8 weeks
postpartum and includes non-specific symptoms such
as fever, vomiting, diarrhoea, and poor feeding. To
date, little information is available for the appropriate
treatment of cases of congenital malaria and in patients of
less than 5 kg bodyweight. Therefore, weight adjusted
treatment with artemether/lumefantrine, dihydroartemi-
sinin/piperaquine and atovaquone/proguanil may be
considered for this indication.
Pregnant women
Pregnant women are at increased risk for malaria related
morbidity and mortality. This increased risk extends to
the post-partum period [107]. Pregnant women present-
ing with acute malaria require prompt and effective
treatment. Malaria in pregnancy is no indication for
Table 5 Paediatric Patients
Drug Dosage Comment
Artemether/Lumefantrine
(Riamet™, Riamet Dispersible™)
(20/120 mg)
5–14 kg: 1 tablet per dose Registered for treatment of patients of ≥5 kg
body weight
15–24 kg: 2 tablets per dose Dispersible drug formulation is registered
in Switzerland
25–34 kg: 3 tablets per dose
> 35 kg: 4 tablets per dose
for 6 doses (0–8–24–36–48–60 h)4
Dihydroartemisinin/Piperaquine
(Eurartesim™)°
5 - < 7 kg: ½ tablet 160 mg/20 mg Registered for treatment of patients of ≥5 kg
body weight
7 - < 13 kg 1 tablet 160 mg/20 mg
No paediatric drug formulation, but two strengths
of tablets make use of this ACT feasible in children13 - < 24 kg: 1 tablet 320 mg/40 mg
24 - < 36 kg: 2 tablets 320 mg/20 mg
36 - < 75 kg: 3 tablets 320 mg/40 mg
75-100 kg: 4 tablets 320 mg/40 mg once
daily for three days
Atovaquone/Proguanil
(Malarone™, Malarone Paediatric™)
5–8 kg: 2 tablets Malarone Paediatric Registered for treatment of patients with >5 kg
body weight
9–10 kg: 3 tablets Malarone Paediatric
11–20 kg: 1 tablet Malarone
21–30 kg: 2 tablets Malarone
31–40 kg: 3 tablets Malarone
>40 kg KG: 4 tablets Malaroneonce daily
for three days
Quinine*/Doxycycline Contraindicated in children below 8 years
of age (13 years in some countries)
No drug registration
Loose drug combination
Quinine*/Clindamycin Thrice daily 10 mg/kg quinine plus twice
daily 10 mg/kg clindamycin for 7 days
No drug registration
Loose drug combination
Mefloquine (Lariam™) 5 - 10 kg: ½ - 1 tablet Registered for treatment of patients of ≥5 kg
body weight
10–20 kg: 1–2 tablets
20–30 kg: 2–3 tablets (2 + 1)
30–45 kg: 3–4 tablets (2 + 2)
45–60 kg: 5 tablets (3 + 2)
> 60 kg 6 tablets (3 + 2 + 1)
20-25 mg/kg total dose divided in 1–3 doses
6 hours apart
*Quinine dose provided as quinine sulphate.
°Eurartesim tablet strengths are Dihydroartemisinin/piperaquine 20 mg/160 mg (children) and Dihydroartemisinin/piperaquine 40 mg/320 mg (adults).
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caesarean section due to the low risk for vertical trans-
mission. Suggested treatment for uncomplicated malaria
in pregnant women is shown on Table 6. In complicated
malaria, effective treatment with artesunate should be
used to save the life of the mother even if there are safety
concerns regarding the drug used. Quinine, chloroquine,
clindamycin and proguanil are considered safe in the first
trimester (Table 6). A recent database analysis of women
exposed to mefloquine around the time of conception
and in the first trimester showed no increased risk of mal-
formations in offspring born to women who were exposed
to mefloquine. Most of the women were exposed to
chemoprophylactic doses rather than treatment doses of
mefloquine [108].
Pregnant women presenting with malaria in the first tri-
mester should be treated with quinine and clindamycin
for 7 days. Artesunate and clindamycin for seven days
can be used if there is treatment failure with the quinine/
clindamycin combination [80] (Table 6). Currently there
is inadequate data on the use of ACT in the first trimes-
ter. Published data on 123 women exposed to ACT treat-
ment in the first trimester showed no adverse outcomes.
More data are available on ACT use in the second and
third trimester (over 1,500 documented reports) and
the WHO guidelines suggest that ACT should be used.
Currently, there is insufficient evidence (154 cases) to rec-
ommend dihydroartesmisinin/piperaquine in pregnancy
[109], so that artemether/lumefantrine is the only viable
ACT option in Europe. Alternatives to artemether/lume-
fantrine in the second and third trimesters are quinine
plus clindamycin or artesunate plus clindamycin [110] for
7 days in each case, or mefloquine monotherapy for
regions without multidrug resistant parasites. Primaquine
and tetracyclines should not be used in pregnancy. Atova-
quone/proguanil is not recommended in pregnancy due
to lack of data, but can be used in situations where no
other drugs are available.
Treatment of P. vivax, P. ovale, P. malariae and P. knowlesi
Plasmodium ovale and P. malariae generally remain
sensitive to chloroquine in all endemic areas, despite
reports of delayed parasite clearance time [111]. Plasmo-
dium vivax sensitivity to chloroquine has declined stead-
ily in Indonesia, Peru and Oceania [79] and a paradigm
shift is imminent, with opinion leaders beginning to call
for a switch to ACT as the drug of choice in Indonesia,
Peru and Oceania. The use of artemether/lumefantrine
has been suggested as a pragmatic choice in areas with
chloroquine-resistant P. vivax [112] and it may also be
used in mixed infections of P. falciparum with this para-
site or with P. ovale or P. malariae [113]. Mefloquine
(15 mg/kg body weight as a single dose) has been found
to be highly effective against P.vivax with a treatment
success of 100% [114]. Monotherapy with doxycycline
(100 mg twice a day for 7 days) results in poor cure
rates against P. vivax [115]. Monotherapy with artemisi-
nins alone should not be used, except for intravenous
artesunate therapy in the initial stages of treatment
for severe infection. Quinine is also effective against
chloroquine resistant P. vivax, but it is not an ideal
treatment because of low tolerability and it may lead to
early relapses [114]. First-line treatment is chloroquine
with ACT as second line if the response to chloroquine
is poor.
Plasmodium vivax and P. ovale infections, but not
P. malariae, require treatment with primaquine (PQ)
for 14 days to eradicate liver hypnozoites and thus
prevent relapses. Plasmodium vivax strains with
reduced susceptibility to primaquine are found in
southern regions of Oceania and South-East Asia and
require a higher dose of primaquine (up to 0.75 mg/
kg/day, max 30 mg per day) for 14 days to prevent
relapses [116]. The CDC recommend routine use of
30 mg per day in adults tested negative for G6PD de-
ficiency [117], and this should be standard treatment
Table 6 Malaria treatment in pregnancy
Uncomplicated falciparum malaria
1st trimester (1) First line Quinine-clindamycin quinine monotherapy
2nd and 3rd trimester First line artemether-lumefantrine
Second line quinine-clindamycin quinine monotherapy mefloquine (2)
Complicated falciparum malaria
1st trimester First line i.v. quinine (+ follow on treatment)
2nd and 3rd trimester First line i.v. artesunate (+ follow on treatment)
Second line i.v. quinine (+ follow on treatment)
P. ovale, P. malariae and P. vivax (3)
All trimesters First line Oral chloroquine
2nd and 3rd trimester Second line Oral ACT
1. Artemether/lumefantrine is not the first drug of choice due to lack of data on lumefantrine in pregnancy, but should be used if quinine is not available.
2. http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html.
3. Primaquine should not be used because of the risk of foetal haemolytic anaemia.
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for adult patients with P. vivax and P. ovale after G6PD
testing according to the CDC [117]. Other centres use the
higher dose only for P. vivax. Primaquine should be admi-
nistered concomitantly with the blood schizonticide or as
soon as possible after treatment.
Primaquine is contraindicated in patients with defi-
ciency of the enzyme glucose-6-phosphate dehydrogen-
ase [118]. In patients with mild G6PD deficiency the
WHO suggests using an intermittent primaquine regi-
men of 0.75 mg base/kg once a week for eight weeks
[79,119]. Patients with significant G6PD deficiency
should be referred for expert advice. A study of prima-
quine 0.5 mg/kg/day in children where G6PD deficiency
was excluded found good tolerability [120].
Treatment of P. knowlesi, a well-know primate malaria
species that has recently recognized as causing a signifi-
cant number of human malaria cases in South-East Asia
and especially Malaysian Borneo, is not standardized,
and WHO has not yet provided recommendations [79].
Evidence is fast accumulating that, like P.falciparum,
P. knowlesi may cause severe cases, with fatality rates
as high as 27%, especially in older or female patients.
Uncomplicated P. knowlesi cases can be treated with
ACT, chloroquine, quinine, or atovaquone/proguanil
[121]. Mefloquine may not be recommended in the light
of case reports of treatment failure. There is no clear evi-
dence of latent liver stages in P. knowlesi, and they have
not been described in animal models [122,123]. A recent
study showed that ACT cleared parasites faster than
comparator antimalarials. In severe P. knowlesi cases, the
use of IVA was associated with a lower case-fatality rate
(17% vs 31%) and lower median parasite clearance time
(2 days vs 4 days) than IVQ [124]. Thus uncomplicated
P. knowlesi should be treated with chloroquine or an
ACT drug and complicated P. knowlesi with IVA.
Interactions
The effect of food on the absorption and pharmacokin-
etics of anti-malarials is important (Table 3). In general,
orally administered agents are given with food to
enhance absorption. The exception is dihydroartemisinin/
piperaquine which should be administered fasting, as
studies have shown that this reduces the possible QTc
prolongation impact of piperaquine [Eurartesim – EMA
summary of Product Characteristics]. Conversely, for arte-
mether/lumefantrine a fatty meal is recommended to
achieve therapeutic levels of the fat soluble lumefantrine.
The most prominent drug/drug interaction is the
effect on QTc-prolongation with quinine, artemether/
lumefantrine as well as with mefloquine. The effect
of the individual drugs can be enhanced if they are used
together, consecutively, or at the same time as other car-
dioactive drugs, such as ketoconazole or phenothiazines.
Quinine and atovaquone/proguanil can enhance the
effect of anticoagulants. Concomitant treatment with
rifampicin, metoclopramide or tetracycline can result in
a lower plasma concentration of atovaquone/proguanil.
Treatment of HIV/malaria co-infected patients has
potential for drug interactions (Table 7). A recent
paper examining the co-administration of artemether/
lumefantrine with lopinavir/ritonavir, showed significant
increases in lumefantrine blood levels but decreases in
artemether blood levels [125]. Further studies are needed
to assess the clinical importance of antiretroviral anti-
malarial drug interactions.
Table 7 Drug interactions between antimalarial and antiretroviral medication
Drugs Mefloquine Atovaquone Proguanil Chloroquine Artemisinins Quinine
Protease inhibitors
Saquinavir - + - - ? +
Ritonavir - + + + + +
Indinavir - + - - ? +
Nelfinavir - + - - ? +
Amprenavir - + - - ? +
Lopinavir - + - - + +
Atazanavir - + - - ? +
NNRTIs (1)
Nevirapine, efavirenz and others - - - - ? +
NRTIs (2)
Zidovudine and others - - - - - -
(1) Non-Nucleoside Reverse Transcriptase Inhibitors.
(2) Nucleoside Reverse Transcriptase Inhibitors.
-No clinically significant interaction, or interaction unlikely based on knowledge of drug metabolism.
+Potential interaction that may require dose monitoring, alteration of drug dosage or timing of administration.
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Conclusions
All hospitals in Europe should have plans for diagnosing
and managing patients with malaria. Obtaining a travel
history is mandatory for all patients with fever. If RDTs in-
dicate the diagnosis of malaria but microscopy cannot be
performed adequate treatment should be started straight
away and the patient promptly transferred to a health care
facility where microscopy can be done. In the case of a
negative RDT but high suspicion of malaria, patients
should also be transferred to a centre with expertise in the
microscopic diagnosis of malaria. ACT should be available
for treatment of uncomplicated malaria and intravenous
artesunate available for severe or complicated malaria.
Intravenous quinine should be available if it is not possible
to maintain a stock of intravenous artesunate.
A standing committee is proposed to harmonize
guidelines as far as possible, whilst recognizing the need
in some areas for individual/country-specific decision-
making. The main recommendations for non-specialist
physicians are summarized on Table 8.
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